Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
arcticnovartis

  • Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap
  • WHO prequalification key milestone for donor-funded and public sector purchasing by UN and other procurement agencies
  • Novartis making treatment available on largely not-for-profit basis in areas where malaria is endemic
/by
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
arcticnovartis

  • Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population health

  • Scales program footprint from 11 countries to more than 30 by 2030, including across five cities in the U.S.

  • Builds on pilot programs that demonstrated significant increase in control rates for high blood pressure in pilot settings
/by
Working with communities to close gaps in heart disease and cancer care

Working with communities to close gaps in heart disease and cancer care
metzgma4

/by
Managing Quality of Life with CML

Managing Quality of Life with CML
halesmi2

/by
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
arcticnovartis

  • Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1
  • 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1
  • Fabhalta granted priority review by FDA for traditional approval

Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN).

/by
Novartis withdraws EMA application for adding new indication for Pluvicto®

Novartis withdraws EMA application for adding new indication for Pluvicto®
weberfr8

/by
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
arcticnovartis

– Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases
   
– Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression
   
– Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience
  

/by
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
arcticnovartis

  • New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented

  • Long-term Cosentyx® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasis

  • Additional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab 

/by
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
arcticnovartis

  • Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer 
  • The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3Kα mutations in breast cancer while sparing wild-type PI3Kα, thus reducing unwanted side effects and improving tolerability
/by